Stay updated on Nivolumab Plus Bevacizumab in GBM Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Bevacizumab in GBM Clinical Trial page.

Latest updates to the Nivolumab Plus Bevacizumab in GBM Clinical Trial page
- CheckyesterdayChange Detected- A site-wide notice about a lapse in government funding and NIH Clinical Center status was added, and a revision note indicates v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check8 days agoChange DetectedShow glossary feature added to the study page. Metadata wording and revision indicator updated (Last Update Submitted that Met QC Criteria, No FEAR Act data capitalization, and Revision: v3.4.0).SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRevision: v3.3.4 was added and the previous revision v3.3.3 was removed; this is a minor version update with no impact on study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check44 days agoChange DetectedA unified 'Locations' section now lists Massachusetts and Ohio, replacing the prior separate 'Massachusetts Locations' and 'Ohio Locations' entries. The footer link to 'HHS Vulnerability Disclosure' has been removed and the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.3%

- Check73 days agoChange DetectedPublications are now described as automatically filled from PubMed and may not be about the study. The page revision is updated to v3.3.2.SummaryDifference0.1%

- Check80 days agoChange DetectedRemoved the general government funding status notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Nivolumab Plus Bevacizumab in GBM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Bevacizumab in GBM Clinical Trial page.